
This infographic highlights how PN is driven by type 2 inflammation, linking immune dysregulation, fibroblast activation, and neuronal dysfunction to nodule formation. It also shows how cytokine-mediated changes in neuronal architecture increase excitability and chronic itch, where resulting lesions and scarring significantly impact patients’ psychological well-being.
This is the ADVENT-branded video of the IDEF presentation that was presented during the 1-hour webinar on December 1st featuring both Dr. Sarina Elmariah and Dr. Jason Hawkes.

Welcome to the PN learning hub focused on key scientific education on bullous pemphigoid, featuring ADVENT resources.
Join experts Drs. Raja Sivamani and Sarina Elmariah as they discuss the clinical signs and high patient burden of PN, explore PN pathophysiology, and examine diagnostic challenges.
Professor Matthias Augustin highlights the high prevalence of both atopic and non-atopic comorbidities in patients with PN, including increased risks of cardiovascular events and all-cause mortality.
Explore the clinical features, complex burden, and underlying mechanisms of PN.

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.
Professor Matthias Augustin details the various clinical manifestations of prurigo nodularis, illustrating how different lesion types can present concurrently in patients.
Professor Sarina Elmariah describes how IL-4 and IL-13, key drivers of type 2 inflammation, uniquely contribute to manifestations of prurigo nodularis beyond itch.
Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.